7D2A Stock Chart & Stats
€1.04
>-€0.01(-0.41%)
At close: 4:00 PM EDT
€1.04
>-€0.01(-0.41%)
Day’s Range― - ―
52-Week Range€0.67 - €1.41
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€107.54M
Enterprise Value€778.04
Total Cash (Recent Filing)€51.79M
Total Debt (Recent Filing)€7.32M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Oct 22, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding99,336,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€18.82M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces solvency and refinancing risk while preserving financial flexibility. This balance-sheet cushion can help Sedana fund commercialization and product development despite current operating losses.
High Gross-margin ProfileA strong gross margin indicates meaningful product economics and potential operating leverage if revenue recovers. Sustained margin quality could support future profitability once sales scale and fixed commercial costs are absorbed.
Recurring Device-and-drug Revenue ModelThe proprietary administration device and Sedaconda isoflurane create a linked workflow with repeat purchasing potential. A growing installed base of ICUs could therefore support durable consumables demand and strengthen customer retention.
Bears Say
Material Revenue ContractionThe sharp reversal suggests weakening commercial traction or adoption and limits the company’s ability to reach scale. Continued contraction would make it harder to leverage the high gross margin and cover fixed operating costs.
Persistent Operating And Net LossesSedana has not yet demonstrated a profitable operating model despite its product focus and gross margin. Ongoing losses indicate that commercial, development, or administrative costs remain too high relative to current revenue.
Sustained Cash BurnRepeated cash consumption increases reliance on existing reserves or future financing to sustain operations and commercialization. Even with low leverage, prolonged negative free cash flow could reduce strategic flexibility and shareholder value.
Sedana Medical AB News
7D2A FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was €0.67 and its highest was €1.41 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is €107.54M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Oct 22, 2026 which is in 56 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Jul 17, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.008 by -€0.001.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is >-0.01.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.008. Following the earnings report the stock price went up 0.667%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in DE:7D2A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical tools designed for delivering volatile anesthetics, alongside the Sedaconda Syringe (a 50/60ml syringe) and a Sedaconda ACD starter kit. The company also provides FlurAbsorb and FlurAbsorb-S, active carbon filtration systems engineered to collect residual anesthetic gases discharged by ventilators. Complementing these are the FlurAbsorb accessory kit, which facilitates connecting ventilator exhausts and gas monitors to the filters, and the FlurAbsorb mount, used to secure the filter during anesthetic gas removal. Further offerings encompass the AMG-06 Gas Monitor, which enables ongoing, non-invasive sidestream measurement of carbon dioxide and anesthetic levels in inhaled and exhaled breaths. Additionally, they supply the Sedaconda Filling Adapter, a disposable tool for securely and simply transferring isoflurane from its container to a Sedaconda Syringe, as well as an array of supplemental items like DRYLINE II Water Traps, the WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Lines. Established in 1999, Sedana Medical AB (publ) maintains its corporate headquarters in Danderyd, Sweden.